Choosing GLP-1 Options for Men

At a glance

• Discuss muscle strength, nutrition and sleep as well as weight.
• Address pregnancy, contraception or menopausal symptoms when relevant.
• Ask which other conditions the program can manage or coordinate.

The question this guide answers

For men, compare the clinical indication and support for sleep apnea, cardiometabolic risk and everyday strength. Gender-focused branding does not prove that one medicine works better.

Sources: NIA: menopauseWegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Separate weight treatment from the rest of health

Menopausal symptoms, reproductive concerns, sleep apnea and cardiometabolic risks each need their own assessment. A GLP-1 weight-management prescription does not replace treatment for hot flashes, androgen symptoms, mood changes or sexual-health concerns.

Marketing aimed at men or women can make a program easier to find, but branding is not evidence that a medication is more effective in that group.

Sources: NIA: menopauseWegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Preserve nutrition and daily function

Reduced appetite can make it harder to eat adequately. Discuss a realistic food plan and activity that helps preserve strength. Changes in energy, exercise tolerance or the ability to do ordinary tasks deserve attention even when the scale falls.

Protein and supplement needs depend on age, diet, kidney function and other conditions. Do not apply a universal high-dose supplement regimen because it is labeled for GLP-1 users.

Sources: NIA: menopauseWegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Bring reproductive plans into prescribing

Weight-loss medicines should be reviewed before pregnancy or breastfeeding. Tirzepatide and orforglipron have specific guidance about oral contraception. Ask about the label for the actual product and make a plan before changing medicines.

For menopausal care, distinguish evidence for managing obesity from claims that the medicine treats menopause itself. Hormone therapy decisions belong in their own benefit-risk discussion.

Sources: NIA: menopauseWegovy prescribing informationZepbound prescribing informationFoundayo prescribing information

Sources and review boundaries

Source check dates are listed below. First-party pages support descriptions of a service’s public offer; medical references support the educational context. They do not establish an independent clinical audit of a provider. This is general education, not personal medical advice; no named licensed clinical reviewer has reviewed this article.

1. NIA: menopauseMedical or regulatory source · Source reviewed · 2026-10-02
2. Wegovy prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02
3. Zepbound prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02
4. Foundayo prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02